Clinical Trial of SOT102 Antibody Drug Conjugate in Patients With Advanced Gastric and Pancreatic Adenocarcinoma

NCT05525286 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

31

Enrollment

INDUSTRY

Sponsor class

Stopped Trial terminated by Sponsor based on benefit- risk reassessment

Conditions

Pancreatic Cancer

Interventions

DRUG: SOT102

Sponsor

SOTIO Biotech a.s.